Akeso used ESMO coverage to detail how ivonescimab’s PD-1xVEGF bispecific program improved survival in a late-stage, China-only biliary tract cancer study. The company’s update also set up side-by-side positioning versus pembrolizumab-style PD-1 benchmarks, as it looks to extend the drug’s differentiation in a competitive immuno-oncology landscape. The communication is tied to the Summit Therapeutics partnership, reflecting the role of co-development in progressing targeted immune strategies for hard-to-treat gastrointestinal malignancies. While details on endpoints and magnitude are limited in the provided excerpt, the company’s emphasis on survival signals an intent to convert early interest into late-stage momentum. For biotech stakeholders, the headline is the strengthening of the bispecific oncology toolkit beyond solid tumor settings where antibody combinations have already shown activity, potentially influencing future trial designs and partner negotiations in hepatobiliary oncology.